Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



A Dose Escalation Study Of PF?06939999 In Participants With Advanced Or Metastatic Solid Tumors

Multiple Cancer Types

This is a Phase 1, open label, multi center, dose escalation and expansion, safety, tolerability, PK, and pharmacodynamics study of PF 06939999 in previously treated patients with advanced or metastatic cancer.
Bladder, Cervical, Esophageal, Head/Neck, Lung, Non Small Cell, Phase I, Uterine
I
Berlin, Jordan
NCT03854227
VICCPHI1909

Multimodality Therapy before and after Surgery in Patients with Squamous Cell Carcinoma of the Head and Neck

Head/Neck

This phase II clinical trial studies how well multimodality therapy works before and after surgery in patients with squamous cell carcinoma of the head and neck. Immunotherapy with monoclonal antibodies, such as durvalumab, may induce changes in body’s immune system and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as carboplatin, nab-paclitaxel, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving carboplatin, nab-paclitaxel, and durvalumab before surgery and using durvalumab with or without radiation therapy and cisplatin after surgery may kill more tumor cells in patients with head and neck cancer.
Head/Neck
II
Gibson, Mike
NCT03174275
VICCHN1890

A Study of CDX-3379 and Cetuximab and in Patients With Advanced Head and Neck Squamous Cell Carcinoma

Head/Neck

This is a study to determine the clinical benefit (how well the drug works), safety and tolerability of combining CDX-3379 and cetuximab. The study will enroll patients with advanced head and neck squamous cell carcinoma who have previously received cetuximab and progressed.
Head/Neck
II
Gibson, Mike
NCT03254927
VICCHN1891

Safety and Efficacy of Tipifarnib in Head and Neck Cancer With HRAS Mutations and Impact of HRAS on Response to Therapy

Head/Neck

An international, multicenter, open-label, 2 cohort, non-comparative, pivotal study evaluating the efficacy of tipifarnib in HRAS mutant HNSCC (AIM-HN). The first cohort will assess the objective response rate (ORR) of tipifarnib in subjects with HNSCC with HRAS mutations. The second study cohort, SEQ-HN, is an observational sub-study and includes 2 types of patients: (1) the historical record of first line therapy in subjects with HRAS mutant HNSCC participating in Cohort 1 in whom first line outcome data are available and (2) matched control HNSCC patients in whom HRAS mutations were not identified (wild type HRAS HNSCC) and who consent to provide first line outcome data and additional follow up.
Head/Neck
II
Gibson, Mike
NCT03719690
VICCHN18117

Study of Monalizumab and Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Head/Neck

The objective of this study is to evaluate in a 3 +3 design, the safety of escalating doses of Monalizumab given IV in combination with cetuximab in patients who have received prior systemic regimen(s) for recurrent and / or metastatic squamous cell carcinoma of the head and neck (SCCHN). Cohorts expansion will evaluate antitumor activity of monalizumab and cetuximab with or without anti-PD(L)1
Head/Neck
I/II
Gibson, Mike
NCT02643550
VICCHN18170

Head and Neck Tumor Tissue Repository and Clinical Database

Head/Neck

Head/Neck
N/A
Kim, Young Jun
NCT00898638
VICCHN0356

A Phase 1 Study in Patients With HPV+ Recurrent / Metastatic Head and Neck Squamous Cell Carcinoma

Multiple Cancer Types

This is a multi center, open-label, phase 1 dose escalation and expansion study evaluating the safety, anti-tumor effect, and immunogenicity of CUE-101 in patients with recurrent / metastatic head and neck squamous cell carcinoma (HNSCC).
Head/Neck, Phase I
I
Gibson, Mike
NCT03978689
VICCPHI1981

Characterization of Central Pain Syndrome in Survivors of Head and Neck Cancer

Head/Neck

This trial studies the characterization of central pain syndrome in survivors of head and neck cancer. Many head and neck cancer patients have pain after they have completed treatment. Cancer and its treatment may change how the brain manages pain. This can make treatment of post-treatment pain more challenging for health care provides. This trial is being done to better understand how the brain is responding to pain.
Head/Neck
N/A
Lou, Dianne
NCT04128267
VICCHN1982

Cancer Patient Safety Learning Laboratory (CaPSLL): Preventing Clinical Deterioration in Outpatients

Multiple Cancer Types

Head/Neck, Lung
N/A
Weinger, Matthew
VICCMD1998

Construction and Validation of an Oral Health Screening Tool in Head and Neck Cancer Survivors Who Received Chemotherapy or Radiotherapy

Multiple Cancer Types

Head/Neck, Supportive Care
N/A
Smith, Derek
VICCSUPP19107

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: